Prevalence of hypometabolism in AD‐related regions in real‐world FDG‐PET of the brain

Background Standard of care for many cancer workups includes whole‐body FDG PET/CT before, during, and after therapy. At Vanderbilt, these scans include the brain for every patient (>20,000 patients). Brain FDG PET is a validated assessment of neuronal health. We will use these standard of care FDG PET images as incidental screening opportunities to evaluate neuronal health to leverage in future electronic health record (EHR) research. Methods Demographic data and FDG images were extracted from Vanderbilt’s EHR for the most recently imaged 1000 patients. Brain images were extracted, quality control was performed, and SUVR for an established AD meta‐region of interest (ROI) was calculated (Landau, et.al, 2011) as were SUVR for AD‐related ROIs including parietal and temporal lobes. We evaluated the prevalence of a positive AD metaROI (SUVR =65 years old were included in this analysis. Most common indications for imaging included lymphoma, melanoma, and head and neck and lung cancers. 159 have >=2 FDG, with an average follow up time of 338 days between staging and follow‐up scans. 272 patients (68.6%) had a positive AD metaROI (20,000) and comparison to age‐matched controls is ongoing.